Description
AttentionA: In our store, products from Zhengzhou Pharmaceutical are protected by a special hologram on the packaging.
- Manufacturer: Zhengzhou Pharmaceutical
- Release form: 1mg 25 tab
- Active ingredient: Anastrozole (Anastrozole)
- Country: China
The active ingredient of Zhengzhou Anastrozole has the same name anastrozole and is a third-generation aromatase inhibitor, which also includes vorozole and letrozole. Exedrol or even mesterolone can be called a partial analogue of it, they block the aromatase enzyme, but unlike the described substance, they are steroid drugs with a certain androgenic activity.
Zhengzhou Anastrozole has a wide popularity in sports practice, especially among experienced athletes conducting heavy courses. Here it is used as an antiestrogen adjunct during the course itself (not post-cycle therapy) to prevent/minimize estrogenic side effects (which include fluid retention and gynecomastia, among others).
Zhengzhou Anastrozole is a powerful antiestrogen, considered one of the strongest among analogues, reviews of the drug confirm this. Its use is advisable either from the beginning of the course with an obvious risk of developing estrogen side effects (for preventive purposes), or when their first symptoms appear (for treatment).
The mechanism of action of Anastrozole is strikingly different from drugs such as tamoxifen and clomiphene, which, like him, are common in sports.It has been observed that the drug blocks the aromatase enzyme, preventing the very process of estrogen formation, while tamoxifen and clomiphene act as estrogen receptor blockers.
When following the recommendations of Zhengzhou Anastrozole, it is a relatively harmless drug to use, however, side effects may occur with abuse or individual predisposition. Probable here are violations of the central nervous system (headaches, drowsiness, asthenia), protein metabolism (raising cholesterol) and the gastrointestinal tract (nausea, vomiting, loss of appetite, diarrhea, even anorexia).
|
Reviews
There are no reviews yet.